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Conclusion: Women admitted with decompensated heart failure appear to have better at dosages used in standard preparations of over-the-counter multivitamins. Therefore, 
survival than men after hospital discharge. These results suggest that biological differ- the addition of beta carotene to multivitamin preparations should cease and the routine 
ences in the progression of heart failure are present even with advanced disease. use of these multivitamins by consumers should be discouraged. 
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1193-51 Treatment and Outcomes of Eastern European Patients 
With Acute Coronary Syndromes in a Multinational 
Randomized Clinical Trial 
Olaa S. Gurieva, Gene Bukhman, Sabina Murphy, Christopher P. Cannon, the OPUS- 
TIMI 16 Investigators, Ukrainian Institute of Cardiology, Kiev, Ukraine, Brigham and 
Women’s Hospital, Boston, MA 
Background: Registries and clinical trials have offered limited evidence on the transla- 
tion of non-ST segment elevation acute coronary syndrome (ACS) trial findings into local 
practices in Eastern Europe (EE). We examined differences in ACS treatment and out- 
comes between EE and other regions in OPUS TIMI-16. a randomized trial of prolonged 
oral alvcoprotein Ilb/llla inhibition. 
1169-57 A Targeted Approach to Reducing Radiation Exposure 
in the Cardiac Catheterization Laboratory 
Samir V. Germanwala Venkatraman Srinivasan, Leslie Boltey, Holly James, Alan 
Gradman, The Western Pennsylvania Hospital, Pittsburgh, PA 
Background: Exposure to ionizing radiation IS an inevitable consequence of therapeutic 
procedures performed in the catheterization laboratory. The risk of radiation-induced 
injury is dose-dependent and nurnemus injuries secondary to lengthy fluoroscopic times 
are reported annually to the Food and Drug Administration. In July 2001, we imple- 
mented a multifaceted program designed to reduce radiation exposure. 
Methods: Physicians and staff were required to demonstrate proficiency with a manda- 
tory radiation-safety curriculum. In addition, fluoroscopic exposure time was documented 
and tracked during each procedure. Operators were informed at ten-minute intervals 
beginning after 30 minutes of exposure and warned if they were approaching a pre-deter- 
mined threshold (60 minutes) associated with documented risk of radiation-induced skin 
injury. To determine the effectiveness of this program, we compared fluoroscopic times 
in 1,067 patients undergoing interventional procedures during the six-month interval 
before (n=569) and after (n=516) program implementation. 
Results: Average fluoroscopic exposure time decreased from 14.5i3.1 to 9.7i3.7 min- 
utes (pcO.O3), a reduction of 31%. Furthermore, there was a 35% reduction in the num- 
ber of patients sustaining prolonged fluoroscopic exposure (> 40 minutes). There was no 
statistical difference in baseline characteristics of the two groups or in the percentage of 
patients in whom factors expected to prolong fluoroscopic exposure time (multi-vessel 
intervention, Intravascular ultrasound, measurement of fractional flow reserve or brachy- 
therapy) were present. 
Conclusion : Didactic education and real time feedback to physicians during Interven- 
tional procedures reduced average fluoroscopic exposure times and the number of 
patients exposed to prolonged irradiation by approximately one-third. Easily replicable, 
this simple program could significantly reduce the dangers of radiation exposure during 
interventional cardiology procedures. 
1169-56 Beta Carotene Increases All-Cause Mortality and 
Cardiovascular Death: A Pooled Analysis of 
Randomized Trials 
Deepak P. Vivekananthan, Marc S. Penn, Shelly S. Sapp, Eric J. Topal, The Cleveland 
I ‘. Cknlc Foundation, Cleveland, OH 
Background: Beta carotene supplementation has been previously found to be associ- 
ated with adverse outcomes in patients at high-risk for lung cancer. However, the impact 
of beta carotene treatment on mortality in patients across the spectrum of cardiovascular 
risk has not been well-studied. Therefore, we performed a pooled analysis of randomized 
trials of beta carotene therapy in both low-risk and high-risk patients. 
Methods: We pooled the results of four trials which randomized patients to either beta 
carotene or control therapy. Only trials which included 1000 or more patients were 
included in the analysis. The dose of beta carotene ranged from 20mg to 50mg. 
Results: Four trials, enrolling 90,054 patients fulfilled the inclusion criteria. The pooled 
, all-cause mortality rate was 10.5% in the beta-carotene arm and 9.9% in the control arm. 
The odds ratio of death for patients treated with beta carotene was 1.07 (1.02. 
1.12;P=O.O03). The rate of death from cardiovascular causes was 4.9% in the beta caro- 
tene group and 4.5% in the control therapy group. The odds ratio for cardiovascular 
death with beta carotene therapy was 1.1 (1.03-1.17; P=O.O03). There were no signifi- 
cant differences in rate of cerebrovascular accident between patients treated with beta 
carotene and those treated with control therapy (4.1% vs. 4.2%, respectively; P=O.59). 
The Breslow-Day test for homogeneity of the odds ratios was not significant (P=O.26). 
Conclusion: Supplementation with beta carotene is associated with a significant 
I increase in all-cause mortality and cardiovascular death in patients at risk for coronary disease. The risk of death from beta carotene therapy appears strongest I” smokers. 
However, a trend towards harm with beta carotene treatment was found even in low-risk 
patients. The adverse effect of beta carotene treatment on all-cause mortality was found 
_. 
Methods: The OPUS-TIM1 16 trial included 10,266 ACS patients at 753 sites in 28 coun- 
tries. Of these patients, 1246 (12.1%) came from 62 sites in the EE countries of the 
Czech Republic, Hungary, Poland, and Russia. Pabents received adjuvant treatments at 
physician discretion. We compared variation in baseline characteristics, treatment, and 
outcomes of patients in EE and other regions of the world (RW). 
Results: We found that EE patients in OPUS-TIM1 16 had more high-risk features at pre- 
sentation. We identified significant variation between EE and other regions in use of adju- 
vant therapies during hospitalization. While only 22.5% of EE patients received 
hypolipidemics versus 39.9% of patients in RW (pcO.OOl), we observed more extensive 
use of angiotensin converting enzyme inhibitors (56.3 versus 36.7 (P<O.OOl)), beta- 
blockers (65.3 versus 46.62 (P<O.OOl)), calcium-channel blockers (6.22 versus 3.92 
(PcO.OOl), and nitrates (64.9 versus 26.8 (P<O.OOl)) in EE. EE patients also underwent 
fewer percutaneous coronary interventions (PCI) (11.66% versus 29.93% (P<O.OOl). 
Patients !n EE had worse outcomes at 30 days. After adjustment for baseline characteris- 
tics and revascularization rates, EE patients had higher rates of death (hazard ratio (HR) 
1.82 (P=O.OOS)). and myocardial infarction (HR 1.64 (P=O.OOl)). These trends persisted 
at 10 months. 
Conclusion: Despite similarities in ACS management guidelines, this study revealed 
disparities in use of hypolipidemic agents and PCI between EE sites and RW in a large 
multinational clinical trial. Given the higher rates of adjusted mortality and myocardial inf- 
arction among EE patients, these findings indicate the need for studies to address the 
sources of treatment and outcome variation, and strategies for improving access to effec- 
tive cardiovascular therapies in EE. 
1193-52 Troponin I Elevation Following Percutaneous Coronary 
Intervention Does Not Predict Future Adverse 
Outcomes 
J. William Phillips, Habib Samady, Linda Snyder, Robert H. Christenson, Jennifer 
Gibson, David E. Bruns, Sharon Sayre. Lawrence W. Gimple. Michael Rag&a, Eric R. 
Powers, Ian J. Sarembock, University of Virginia, Charlottesville, VA 
Background: The importance of troponin I (cTnl) elevation following percutaneous coro- 
narv interventions (PCI) has not been evaluated as extensivelv as CK-MB. This studv 
evaluated the prognostic significance of cTnl elevation following PCI on MACE (death, 
MI, TVR) at three years. 
Methods: We prospectively studied 320 consecutive patients without acute MI who 
underwent successful PCI (mean age 62 +/- 12, males 64%, diabetes 32%. prior Ml 43%, 
CHF 12%, stent use 76%). All patients had blood drawn before and 12-24 hours after 
PCI for cTnl assay on a Dimension @ RxL. Serial follow-up by phone and questionnaire 
occurred at six months. one. two and three “ears. 
Results: Periprocedural cTnl elevation occurred in 192/320 (60%) patients using cTnl > 
0.1 na/mL. Usina cTnl 2 1.5 na/mL elevation occurred in 701320 (22%). a rate similar to 
other studies with CK-MB. Patients with periprocedural elevation of cTnl 2 0.1 ng/mL had 
similar rates of death (9% Versus IO%, p=ns), death and Ml (15% Versus 16%, p=ns) or 
any MACE (33% Versus 32%, p=ns) at 3 years. After controoling for other variables, by 
multivariable logistic regression analysis, cTnl as a continuous variable after PCI was not 
a significant predictor of death (x2 2.7, p=O.lO), death and Ml (x2 1.9, p=O.l7), or death, 
MI, and lVR (x2 0.0, p=O.96) at three years. 
Conclusion: After control for common variables, cTnl elevation following PCI does not 
add prognostic information about future MACE for up to 3 years post-PCI. This may be 
due to a higher sensitivity of cTnl to detect small amounts of myocardial injury that are 
not associated with worse long-term outcomes. This has important implications for the 
design of clinical trials and suggests against the use of cTnl elevation following PCI as a 
primary endpoint. 
